Xenon pharmaceuticals inc. (XENE)
Income statement / Quarterly
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Sep'13
Revenue (note 13):

-

3,500

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration revenue (note 12)

-

-

-

-

-

-

-

-

-

264

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration revenue

-

-

-

-

-

-

-

-

-

-

15

16

374

412

412

569

3,226

4,293

4,044

4,010

-

-

-

-

-

Collaboration revenue (note 10)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

13,192

5,296

5,001

10,786

Royalties

-

-

-

-

-

-

-

-

-

-

-

-

2

1

1

32

-

1

2

-

-

1

2

-

2

Revenues

-

-

-

-

-

-

-

-

-

-

-

-

376

413

413

601

3,227

4,294

4,046

4,010

-

13,193

5,298

-

10,788

Operating expenses:
Research and development

11,752

9,751

8,205

9,137

6,402

6,248

5,416

5,568

6,397

7,164

6,109

5,903

4,396

5,965

5,103

4,364

4,263

3,793

3,669

3,427

3,453

3,216

2,566

2,533

2,577

General and administrative

3,175

2,700

2,307

2,621

2,052

1,938

2,178

2,238

1,670

1,744

1,799

2,100

1,442

1,779

1,676

1,895

1,567

1,321

178

6,720

1,667

1,316

1,213

1,300

1,692

Buy-out of future milestones and royalties (note 14c)

-

-

-

-

-

6,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

14,927

12,451

10,512

11,758

8,454

14,186

7,594

7,806

8,067

8,908

7,908

8,003

5,838

7,744

6,779

6,259

5,830

5,114

3,847

10,147

4,843

4,532

3,920

3,969

4,269

Loss from operations

-11,598

-8,951

-10,512

-11,758

-8,454

-14,186

-7,594

-7,806

-8,051

-8,644

-7,893

-7,987

-5,462

-7,331

-6,366

-5,658

-2,603

-820

199

-6,137

35

8,661

1,378

1,032

6,519

Other income (expense):
Interest income

437

528

706

682

658

325

125

108

95

124

109

149

168

114

123

99

97

130

163

152

152

138

137

141

117

Interest expense

348

363

365

358

357

678

200

159

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

15

Foreign exchange gain (loss)

97

-80

135

130

-425

148

-140

-284

-109

778

404

321

-710

-497

227

2,296

-1,431

-3,137

806

-3,171

1,037

392

-285

200

-243

Gain on termination of collaboration agreement (note 13c)

-

-

-

-

0

0

0

4,398

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss before income taxes

-11,412

-8,866

-10,036

-11,304

-8,578

-14,391

-7,809

-3,743

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income tax recovery

-36

5

-29

37

-20

-8

-8

12

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss and comprehensive loss

-11,376

-8,871

-10,007

-11,341

-8,558

-14,383

-7,801

-3,755

-8,065

-7,742

-7,380

-7,517

-6,004

-7,714

-6,016

-3,263

-3,937

-3,827

1,168

-9,156

1,224

9,191

1,230

1,373

6,378

Net loss attributable to preferred shareholders

422

336

380

430

-76

1,621

1,303

33

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income attributable to participating securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,596

1,230

1,373

5,059

Net loss attributable to common shareholders

-10,954

-8,535

-9,627

-10,911

-8,634

-12,762

-6,498

-3,722

-8,065

-7,742

-7,380

-7,517

-

-

-

-

-

-

-

-

-

3,595

0

-

1,319

Net loss per common share (note 6):
Basic

-

-

-

-0.42

-

-

-

-0.21

-0.45

-0.43

-0.41

-0.42

-0.32

-0.51

-0.42

-0.23

-

-

0.08

-

-

2.67

-

-

0.99

Diluted

-

-

-

-0.42

-

-

-

-0.21

-0.45

-0.43

-0.41

-0.43

-0.32

-0.51

-0.42

-0.23

-

-

-0.07

-

-

1.69

-

-

0.63

Basic and diluted

-

-0.33

-0.37

-

-

-0.63

-0.45

-

-

-

-

-

-

-

-

-

-

-0.27

-

-0.64

-

-

-

-

-

Weighted-average common shares outstanding (note 6):
Basic

-

-

25,773

25,753

-

-

14,306

17,804

17,998

17,998

17,997

17,946

17,902

15,268

14,408

14,394

-

-

14,241

-

-

1,348

1,347

-

1,337

Stock options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

763

-

-

728

Subscription rights

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10

-

-

14

Diluted

-

-

25,775

25,753

-

-

14,306

17,804

18,006

18,009

18,015

17,974

17,876

15,268

14,434

14,394

-

-

15,129

-

-

2,122

1,347

-

2,080

Foreign currency translation adjustment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,999

-1,512

919

-909

-

Comprehensive income (loss)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-775

7,679

2,149

464

-

Basic and diluted

-

25,793

-

-

-

20,306

-

-

-

-

-

-

-

-

-

-

-

14,298

-

14,212

-

-

-

1,345

-